On Monday, IDEAYA Biosciences got a positive adjustment to its Relative Strength (RS) Rating, from 70 to 79.
This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if IDEAYA Biosciences can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
IDEAYA Biosciences has moved more than 5% past a 30.25 entry in a third-stage cup without handle, meaning it's now out of a proper buy range. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company showed 0% EPS growth in the latest quarterly report. Sales gains came in at -100%.
The company earns the No. 209 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
